Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Achillion Readies A Nuc Combo As Acquisition Speculation Swirls

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The biotech can move forward with an HCV combo that includes its Phase I nuc and its protease inhibitor now that FDA has partially lifted the hold on the drug.

You may also be interested in...

Novartis’ Hepatitis C Drug Alisporivir Returns To Clinical Testing Minus Interferon

Phase II trial of alisporivir plus ribavirin began after FDA modified its partial clinical hold; previous regimen included peg-interferon.

With FDA Hold Continuing, Idenix To Focus On NS5A Inhibitor And New Uridine Nucleosides

HCV-focused biotech tells J.P. Morgan conference audience it is making IDX719, its Phase II NS5A inhibitor, its lead program and hopes to start a non-exclusive combination trial with another company’s protease inhibitor this year.

Hep C Nucleoside Scare: FDA Wants Idenix’s CV Safety Data After BMS Event

Idenix announced FDA has placed a partial clinical hold on its hepatitis C candidate IDX184 after Bristol-Myers Squibb was forced to halt a study of its similar drug following a serious cardiovascular event. The news sparked new worries concerning a class effect for nucleoside polymerase inhibitors, though Gilead stood by its candidate GS7977’s clean CV profile and Idenix said no CV toxicities have been associated with ‘184.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts